What is Esperion?
Founded in 2008, Esperion is dedicated to the discovery, development, and commercialization of innovative medicines aimed at improving outcomes for patients at risk for or suffering from cardiovascular and cardiometabolic diseases. The company is actively addressing the limitations of current treatments for high cholesterol, striving to provide next-generation therapies that help patients achieve their LDL-cholesterol goals. Esperion's commitment is driven by the understanding that aggressive LDL-cholesterol reduction is critical for patient health, positioning the company at the forefront of addressing this significant public health challenge.
How much funding has Esperion raised?
Esperion has raised a total of $807.5M across 9 funding rounds:
Private Equity
$5M
Other Financing Round
$33M
Stock Offering
$70M
Stock Offering
$85M
Stock Offering
$189.9M
Stock Offering
$151.9M
Debt
$200M
Other Financing Round
$50M
Private Equity (2010): $5M led by Undisclosed
Other Financing Round (2013): $33M supported by Arboretum Ventures, Alta Partners, Domain Associates, Aisling Capital, and Longitude Capital
Stock Issuance/Offering (2013): $70M, investors not publicly disclosed
Stock Issuance/Offering (2014): $85M, investors not publicly disclosed
Stock Issuance/Offering (2015): $189.9M, investors not publicly disclosed
Stock Issuance/Offering (2017): $151.9M, investors not publicly disclosed
Debt (2020): $200M, investors not publicly disclosed
Other Financing Round (2021): $50M featuring Oberland Capital
Key Investors in Esperion
Oberland Capital
Oberland Capital is a private investment firm focused on funding innovation in the global healthcare industry, managing approximately $3 billion in assets. The firm specializes in flexible investment structures tailored to meet the specific needs of its partners, offering a range of financing solutions including monetization of royalty streams and project-based financing.
Arboretum Ventures
Arboretum Ventures is a Midwest-based healthcare venture capital firm with over 20 years of experience in investing in innovative healthcare solutions. The firm focuses on early-stage startups in under-ventured markets, aiming to improve patient outcomes and reduce healthcare costs through strategic partnerships and investments.
Alta Partners
Alta Partners is a prominent venture capital firm specializing in healthcare and life sciences, dedicated to supporting entrepreneurs in building impactful companies since 1996. The firm focuses on innovative solutions that enhance patient outcomes and challenge existing healthcare paradigms.
What's next for Esperion?
The recent major strategic investment signals Esperion's readiness to accelerate its commercialization efforts and potentially expand its pipeline. This infusion of capital is likely to support further clinical development, regulatory submissions, and market penetration strategies for its existing therapies, as well as fuel research into new therapeutic candidates. With a clear focus on addressing critical unmet needs in cardiovascular health, Esperion is poised to leverage this financing to solidify its market position and continue its mission of transforming patient care in a field where achieving treatment goals is paramount.
See full Esperion company page
